ArticleGynecologic oncology2021

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

Kimberly K Leslie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.